BVF Partners

Company

Related News

Immunic Presents New Phase 2 CALLIPER Data, Secures $400M for Vidofludimus Calcium

May 28, 2026

Immunic presented new Phase 2 CALLIPER data at CMSC 2026 showing vidofludimus calcium's favorable effects in progressive MS, including a novel unified disability endpoint. The company also secured $400M in private placement to fund Phase 3 ENSURE studies and commercial preparations.

Earendil Labs Raises $787M, Immunic Secures $400M in Biotech Funding Surge

Mar 21, 2026

AI-powered drugmaker Earendil Labs secured $787 million to advance biologics for autoimmune diseases and cancer, while Immunic locked in up to $400 million to fund Phase 3 trials of its multiple sclerosis therapy.